United Kingdom (UK)
Recombinant monoclonal antibody to HER1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody 048-006.
UniProt Accession Number of Target Protein: P00533
Alternative Name(s) of Target: Epidermal growth factor receptor; EC:2.7.10.1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
Immunogen: The original antibody was isolated by panning a phage display library against HER1.
Specificity: The antibody is specific for HER1. HER1 is a receptor tyrosine kinase binding ligands of the EGF family. It actives several signaling cascades to convert extracellular cues into appropriate cellular responses.
Application Notes: The antibody was able to inhibit the phosphorylation signal of HER1 in three kinds of cells (renal cell carcinoma (CCF-RC1, Caki-1) and epidermoid cancer (A431)) in a concentration-dependent manner, as shown by western blot analysis. The antibody could inhibit the binding to EGF, using A431 cells. The binding affinity of the original format of the antibody to HER1 was measured by surface plasmon resonance (Kd= 0.48 pM). The IgG1 format of the antibody exhibited ADCC activity in the cell line in which HER1 is expressed (CCF-RC-1, NCI-H1373, HT-29, ACHN and A-431 cell lines). The IgG1 format of the antibody was used in in vivo antitumor experiments. Human lung cancer cells H1373 cells or epidermoid tumor A-431 were transplanted into a mouse so as to produce a tumor and, the antibody was administrated. The antibody significantly reduced the tumor volume compared to the control group. The effect was comparable to ERBITUX when human lung cells H1373 were used (US9388249B2).
Antibody first published in: PMID: